Share: 
Status: 
Active
Rating: 
Average: 4.5 (4 votes)
4.5

Shedding Light on Shingles: The Power of Prevention

Course description

Shingles, or herpes zoster (HZ), is a common secondary infection caused by a reactivated varicella zoster virus (VZV). More than 95% of immunocompetent individuals aged at least 50 years are seropositive for VZV and are therefore at risk for developing HZ. Age-related increased incidence of HZ and its complications are thought to be related to the decline in cell-mediated immunity. Complications of HZ, which create a significant patient and economic burden, may be neurological, ophthalmological, dermatological, or visceral. HZ vaccination is essential for the prevention of HZ and its consequences.

TARGET AUDIENCE

This activity has been designed to meet the educational needs of health care professionals who are involved in the vaccination of adult patients. 

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants will be better able to:

  1. Summarize the pathophysiology and complications of herpes zoster.
  2. Identify various clinical presentations of herpes zoster.
  3. Apply strategies for herpes zoster prevention.

FACULTY

Lawrence Herman, PA-C, MPA, DFAAPA (Moderator)
Dean and Professor, Physician Assistant Studies
Gardner-Webb University, College of Health
 Sciences
Boiling Springs, North Carolina

Myron J. Levin, MD
Professor of Pediatrics and Medicine
University of Colorado School of Medicine
Aurora, Colorado

Susan Rehm, MD
Vice Chair, Department of Infectious Disease
Cleveland Clinic
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
  of Case Western Reserve University
Cleveland, Ohio

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter

Relationship Identified With:

Lawrence Herman, PA-C, MPA, DFAAPA

Consultant/Advisor: Merck & Co., Inc.; Novo Nordisk Inc; Regeneron Pharmaceuticals, Inc.

Speakers Bureau: Novo Nordisk Inc

Myron J. Levin, MD

Consultant/Advisor: Merck & Co., Inc.

Grant/Research Support: GSK group of companies; Medimmune; Merck & Co., Inc. 

Royalties/Patents: Merck & Co., Inc

Spouse/PartnerGrant/Research Support: GSK group of companies; Medimmune; Merck & Co., Inc.

Susan Rehm, MD

Consultant/Advisor: Pfizer Inc.

Stock Ownership: Amgen Inc.; Eli Lilly and Company; Medtronic; Merck & Co., Inc.; Pfizer Inc.


Planners, Managers, Reviewers: Sandy Breslow; Alison Kemp; Kimberly Joab; Bernard M. Abrams, MD; Lyerka Miller, PhD, hereby state that neither they nor their spouse/life partner do not have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months. 

Peer Review

This CME activity has been peer-reviewed by The American Journal of Medicine. 

Financial Support

This activity has been supported by an independent educational grant from Merck & Co., Inc.

Provider Information

Jointly provided by the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC.

CME Credit (Physicians)

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC. The Elsevier Office of Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME INQUIRIES/SPECIAL NEEDS

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.


Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Miller Medical Communications, LLC, and Merck & Co., Inc. do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Credits & accreditation
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician
Course opens: 
05/25/2016
Course expires: 
05/24/2017
Please login or register to take this course.